Sphere Appoints Distributor in Japan

Sphere Medical Holding plc

Sphere Medical appoints Finggal-Link as distributor for Pelorus 1000 in Japan

Cambridge, UK, 21 June 2012: Sphere Medical Holding plc (AIM: SPHR.L), a leading developer of innovative monitoring and diagnostic products for the critical care setting, is pleased to announce that it has appointed FinggalLink Co. Limited as its exclusive distributor for the Pelorus 1000 propofol measurement system in the Japanese market.

Finggal Link, headquartered in Tokyo, is a specialist distributor of medical and life sciences equipment, including a range of in-vitro diagnostic and analytical equipment. The company's sales and service force delivers full geographic coverage across Japan.

The Pelorus 1000 is the world's first commercially available rapid propofol analyser. Propofol is widely used in critical care, for general anaesthesia in the operating room and for sedation in the intensive care unit. The ability to measure and adjust propofol levels is expected to be a key tool in individualising and optimising therapy at the patient level, both in the operating room and the intensive care unit.

Stuart Hendry, CEO of Sphere Medical commented:

"Finggal Link has been supporting our activities in Japan for the last few months and we are very pleased that this has progressed to a full distribution agreement. Japan is an important market for new medical technologies and Finggal Link has a strong record in the introduction of such technologies to the anaesthesiologist".

For further information, please contact:

Notes for Editors

Sphere Medical commenced trading on the AIM, a market operated by the London Stock Exchange (LSE), on 17 November 2011 having raised £14m (£12.8m net of expenses) in a placing of ordinary shares.

Sphere Medical is a UK based medical device company completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere Medical's products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient's bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.